362 related articles for article (PubMed ID: 20035691)
1. [Eculizumab in paroxysmal nocturnal hemoglobinuria].
Socié G; Varoqueaux N; Peffault de Latour R
Med Sci (Paris); 2009 Dec; 25(12):1126-9. PubMed ID: 20035691
[TBL] [Abstract][Full Text] [Related]
2. [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment].
Röth A; Dührsen U; Schrezenmeier H; Schubert J
Dtsch Med Wochenschr; 2009 Feb; 134(9):404-9. PubMed ID: 19224425
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.
Luzzatto L; Gianfaldoni G
Int J Hematol; 2006 Aug; 84(2):104-12. PubMed ID: 16926130
[TBL] [Abstract][Full Text] [Related]
4. [Paroxysmal nocturnal hemoglobinuria: An unknown cause of thrombosis?].
Doutrelon C; Skopinski S; Boulon C; Constans J; Viallard JF; Peffault de Latour R
J Mal Vasc; 2015 Dec; 40(6):384-90. PubMed ID: 26205796
[TBL] [Abstract][Full Text] [Related]
5. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.
Richards SJ; Hill A; Hillmen P
Cytometry B Clin Cytom; 2007 Sep; 72(5):291-8. PubMed ID: 17549742
[TBL] [Abstract][Full Text] [Related]
7. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria.
Brodsky RA
Blood Rev; 2008 Mar; 22(2):65-74. PubMed ID: 18063459
[TBL] [Abstract][Full Text] [Related]
8. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
DeZern AE; Brodsky RA
Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
[TBL] [Abstract][Full Text] [Related]
9. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
Risitano AM
Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
[TBL] [Abstract][Full Text] [Related]
10. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
[TBL] [Abstract][Full Text] [Related]
11. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
Röth A; Dührsen U
Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
[TBL] [Abstract][Full Text] [Related]
12. A new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria.
Shichishima T; Noji H
Hematology; 2002 Aug; 7(4):211-27. PubMed ID: 14972783
[TBL] [Abstract][Full Text] [Related]
13. [Paroxysmal nocturnal hemoglobinuria: from physiopathology to treatment].
Arruda MM; Rodrigues CA; Yamamoto M; Figueiredo MS
Rev Assoc Med Bras (1992); 2010; 56(2):214-21. PubMed ID: 20498998
[TBL] [Abstract][Full Text] [Related]
14. How I treat paroxysmal nocturnal hemoglobinuria.
Brodsky RA
Blood; 2009 Jun; 113(26):6522-7. PubMed ID: 19372253
[TBL] [Abstract][Full Text] [Related]
15. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
Merrill SA; Brodsky RA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
[TBL] [Abstract][Full Text] [Related]
16. New insights into paroxysmal nocturnal hemoglobinuria.
Brodsky RA
Hematology Am Soc Hematol Educ Program; 2006; ():24-8, 516. PubMed ID: 17124035
[TBL] [Abstract][Full Text] [Related]
17. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
Guasch A
Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585
[No Abstract] [Full Text] [Related]
18. Paroxysmal nocturnal hemoglobinuria.
Čermák J
Vnitr Lek; 2018; 64(5):508-513. PubMed ID: 30193519
[TBL] [Abstract][Full Text] [Related]
19. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
